US Coverage

Law360 Authority | Deep News & Analysis

Global Coverage

Law360 Pulse | The Business of Law

Mealeys

MLex

In Re: National Prescription Opiate Litigation

Track this case

Case overview

Case Number:

1:17-md-02804

See also:

Court:

Ohio Northern

Nature of Suit:

P.I.: Other

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

Dan Aaron Polster (MDL 28

Firms

Companies

Government Agencies

Sectors & Industries:

  1. October 10, 2023

    Email Flub In Opioid MDL No Basis For Master's Removal

    The Ohio federal judge overseeing the opioid multidistrict litigation on Tuesday refused to remove a special master who misfired a "reply all" email, saying it "unquestionably" contained private deliberations.

  2. September 28, 2023

    Opioid Special Master's Email Doesn't Betray Bias, Court Told

    The plaintiffs' executive committee in multidistrict opioid litigation against pharmacy benefit managers OptumRX Inc. and Express Scripts Inc. has urged an Ohio federal court to reject their bid to disqualify the special master who sent a misfired "reply all" email.

  3. September 21, 2023

    Opioid MDL Special Master Fights Bias DQ For 'Email Mistake'

    The special master overseeing the massive opioid multidistrict litigation against pharmacy benefit managers OptumRX Inc. and Express Scripts Inc. is fighting a disqualification bid filed following his reply-all flub, telling an Ohio federal judge on Thursday that it is "hokey" but true that every day he reminds himself of the role's "honor and privilege."

  4. September 20, 2023

    Opiate MDL Special Master Faces DQ Bid Over 'Reply All' Goof

    Pharmacy benefit managers OptumRX Inc. and Express Scripts Inc. called for the disqualification of the special master overseeing multidistrict litigation brought against the PBMs over the national opioid epidemic after he allegedly revealed a bias against them in an email they said he inadvertently sent as a "reply all."

  5. September 12, 2023

    Opioid Sales Fell By Half After 2010, DEA Data Shows

    Newly released data from the U.S. Drug Enforcement Administration about prescription opioid sales shows that opioid shipments in 2019 were nearly half of those a decade prior, attorneys in the sweeping opioid litigation said on Tuesday.

  6. August 22, 2023

    Walmart's Opioid Deal Advances With States' Participation

    Walmart revealed in a regulatory filing late Tuesday that it will pay about $2.8 billion of the roughly $3 billion deal it struck to end thousands of lawsuits accusing its nationwide pharmacy network of fueling America's opioid crisis, after an administrator determined enough municipalities have joined the state settlements.

  7. July 14, 2023

    DEA Must Produce Data For Opioid MDL Trials, Judge Rules

    The Ohio federal judge steering multidistrict litigation over the opioid crisis on Friday signed off on a subpoena requesting information on national opioid sales from the U.S. Drug Enforcement Administration, saying the data's importance to the litigation "cannot be overstated."

  8. June 15, 2023

    Hospitals Seek Class Counsel In Opioid MDL

    Hospitals have asked the Ohio federal judge overseeing opioid multidistrict litigation to name Don Barrett of Barrett Law Group as interim class counsel, saying their claims are distinct from those brought by local governments and his appointment would aid settlement talks.

  9. May 17, 2023

    Walgreens To Pay SF $230M After Landmark Opioid Trial Loss

    Walgreens Co. has agreed to pay $230 million to San Francisco for its role in the city's opioid epidemic following a landmark weeks-long bench trial last year that found the pharmacy chain liable for distributing thousands of suspicious painkiller prescriptions in the area without proper screenings, the city announced Wednesday.

  10. May 02, 2023

    Reject 'Carte Blanche' For Risky Opioid Sales, 4th Circ. Urged

    A West Virginia city and county have told the Fourth Circuit that distributors of addictive painkillers misinterpreted state nuisance law and the federal Controlled Substances Act when seeking to uphold a lower court's dismissal of the local governments' multibillion-dollar opioid lawsuit.